WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016178246) PROCESS FOR THE PREPARATION OF ALOGLIPTIN
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/178246    International Application No.:    PCT/IN2016/050122
Publication Date: 10.11.2016 International Filing Date: 03.05.2016
IPC:
C07D 401/04 (2006.01)
Applicants: INDOCO REMEDIES LIMITED [IN/IN]; Indoco House, 166 C. S. T. Road Santacruz (East) Mumbai 400098 (IN)
Inventors: NAIR, Ranjeet; (IN).
RAMESAN, Palangat Vayalileveetil; (IN).
PANANDIKAR, Aditi Milind; (IN)
Agent: P., Aruna Sree; (IN)
Priority Data:
1772/MUM/2015 04.05.2015 IN
Title (EN) PROCESS FOR THE PREPARATION OF ALOGLIPTIN
(FR) PROCÉDÉ DE PRÉPARATION D'ALOGLIPTINE
Abstract: front page image
(EN)The invention concerns a process for the preparation of 2-[[6-[(3R) -3-amino-l-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-l(2H)- pyrimidinyl]methyl]benzonitrile commonly known as alogliptin and its pharmaceutically acceptable benzoate salt. Alogliptin is a dipeptidyl peptidase-4 inhibitor (DPP-4) that is designed to slow the inactivation of incretin hormones glucagon-like peptide-1 (GLP-1) and glucose- dependent insulinotropic peptide (GIP). It is used as antidiabetic drug. Formula (I)
(FR)La présente invention concerne un procédé de préparation de 2-[[6-[(3R)-3-amino-1-pipéridinyl]-3,4-dihydro-3-méthyl-2,4-dioxo-1(2H)-pyrimidinyl]méthyl]benzonitrile communément appelé alogliptine et de ses sel benzoate pharmaceutiquement acceptables. L'alogliptine est un inhibiteur de dipeptidyl peptidase-4 (DPP-4) qui est conçu pour ralentir l'inactivation des hormones incrétines que sont le peptide-1 apparenté au glucagon (GLP-1) et le peptide insulinotropique glucose-dépendant (GIP). Il est utilisé en tant que médicament antidiabétique. Formule (I)
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)